Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K
Principles of Drug Action01:24

Principles of Drug Action

5.6K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.6K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

429
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
429
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

254
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
254
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

377
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
377

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TraNce: Type-aware hypergraph neural network with biological mediators for drug repositioning.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Pelvic schwannoma misdiagnosed as colorectal cancer metastasis and the corresponding diagnostic lessons: A report of two cases.

Oncology letters·2026
Same author

Debiased medication recommendation through fusing frequent pattern and temporal medical records.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Synthesis of one-dimensional silver nanowires in aqueous solution using phloroglucinol as a reducing reagent.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Transcriptomic and single-cell analyses reveal the prognostic value of ETV4 and its role in shaping the immune landscape of colorectal cancer.

Translational oncology·2026
Same author

Multi-modal contrastive learning based on molecular and textual data for drug response prediction.

Neural networks : the official journal of the International Neural Network Society·2026

Related Experiment Video

Updated: May 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Knowledge-Driven and Relation-Aware Synergistic Learning for Drug Repositioning.

Shilong Wang, Yuanxin Liu, Xiaobo Li

    IEEE Journal of Biomedical and Health Informatics
    |April 29, 2025
    PubMed
    Summary
    This summary is machine-generated.

    KRANE enhances drug repositioning by improving knowledge graph analysis for drug discovery. This relation-aware method better captures drug-disease interactions and overcomes noise in training for more stable optimization.

    More Related Videos

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
    07:51

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

    Published on: May 21, 2018

    11.5K
    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    21.0K

    Related Experiment Videos

    Last Updated: May 6, 2026

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    9.6K
    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
    07:51

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

    Published on: May 21, 2018

    11.5K
    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    21.0K

    Area of Science:

    • Pharmacology and Drug Discovery
    • Bioinformatics and Computational Biology
    • Artificial Intelligence in Medicine

    Background:

    • Drug repositioning accelerates drug discovery by identifying new uses for existing drugs.
    • Current knowledge graph (KG) methods struggle with complex drug-disease relationships and synergistic mechanisms.
    • Graph neural network (GNN) and knowledge graph embedding (KGE) methods face challenges with noise and unstable optimization.

    Purpose of the Study:

    • To introduce KRANE, a novel knowledge-driven and relation-aware synergistic learning method for drug repositioning.
    • To address limitations in current KG-based drug repositioning methodologies, particularly in capturing intricate relationships and synergistic effects.
    • To improve the stability and accuracy of drug repositioning models by mitigating noise during training.

    Main Methods:

    • Developed a relation-aware feature extractor (RAFE) using contextual triples attention scores to enhance representation of complex relational features.
    • Implemented a synergistic feature reconstruction module to extract synergistic heterogeneous feature interactions between drugs and diseases.
    • Proposed a knowledge-regulated loss function to minimize the impact of noise on model training and optimize performance.

    Main Results:

    • KRANE demonstrated significant improvements over existing drug repositioning methods across three public datasets.
    • The relation-aware approach effectively captured intricate drug-drug, drug-disease, and disease-disease relationships.
    • Synergistic feature extraction successfully identified underexplored mechanisms between drugs and diseases.

    Conclusions:

    • KRANE offers an effective and robust approach to drug repositioning by enhancing knowledge graph analysis.
    • The method successfully addresses limitations in existing GNN and KGE techniques for drug discovery.
    • KRANE provides a stable and accurate framework for identifying new therapeutic pathways for existing drugs.